Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials

August 21st 2023

The FDA has placed another partial clinical hold on the enrollment of new patients in United States clinical trials evaluating the potential first-in-class investigational anti-CD47 immunotherapy magrolimab for the treatment of acute myeloid leukemia.

Frontline Steroid Treatment for Acute GVHD

August 21st 2023

Drs Gootpu and Inyang explain use of corticosteroids as frontline treatment for acute GHVD.

Assessment and Grading of Acute GVHD

August 21st 2023

Dr Gooptu shares guidance on the assessment and grading of acute GVHD.

TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

August 19th 2023

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

Dr Islam on the Current and Expanding Role of Pirtobrutinib in MCL

August 18th 2023

Prioty Islam, MD, MSc, discusses how the FDA approval of the noncovalent BTK inhibitor pirtobrutinib has transformed the treatment of patients with mantle cell lymphoma, and where this agent fits in to the current treatment armamentarium.

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

August 18th 2023

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Zanubrutinib Sustains Response, Safety Benefits Vs Ibrutinib in Waldenström Macroglobulinemia

August 17th 2023

Zanubrutinib demonstrated long-term efficacy with superior tolerability compared with ibrutinib for the treatment of patients with symptomatic Waldenström macroglobulinemia regardless of CXCR4 or MYD88 mutational status.

Frontline Quizartinib Plus Chemotherapy Shows Curative Potential in FLT3-ITD Wild-Type AML

August 17th 2023

The addition of quizartinib to standard induction and consolidation chemotherapy with idarubicin plus cytarabine followed by maintenance therapy led to an improvement in event-free survival compared with placebo plus chemotherapy in patients with FLT3-ITD wild-type acute myeloid leukemia.

Tazemetostat Plus Lenalidomide and Rituximab Under Investigation in R/R Follicular Lymphoma

August 17th 2023

Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.

Final Thoughts on Recent Data Updates in MDS

August 17th 2023

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

MB-106 Shows Continued Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

August 16th 2023

MB-106, a first-in-class, CD20-targeted autologous CAR T-cell therapy, led to durable clinical responses with low-grade cytokine release syndrome in patients with indolent lymphoma.

Oral ATO/ATRA/Ascorbic Acid Regimen Delivers Durable Responses in APL

August 15th 2023

Harry Gill, MD, discusses the importance of offering patients with APL an entirely oral treatment regimen, key efficacy findings from this trial, and the tolerability of this regimen.

Patient Scenario 2: JAK2 Inhibitors in Myelofibrosis

August 15th 2023

After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.

Momelotinib’s Role in the Myelofibrosis Treatment Paradigm

August 15th 2023

Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.

Dr Chari on the FDA Approval of Talquetamab in Relapsed/Refractory Multiple Myeloma

August 14th 2023

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

FDA Places Clinical Hold on Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML

August 14th 2023

The FDA has placed a clinical hold on the phase 1 PLAT-08 trial evaluating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia.

Acute GVHD Presentation and Diagnosis

August 14th 2023

Acute GVHD presentation and diagnosis is assessed for the clinical scenario previously discussed.

The GVHD Prophylaxis Landscape

August 14th 2023

GVHD prophylaxis techniques are analyzed by the panelists.

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13th 2023

Single-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial.